drugset
drugset / Trial / NCT02261298

ONO-4538 Phase I Study in Patients With Solid Tumor

NCT02261298 ↗

Phase 1 Completed 18 enrolled Ono Pharmaceutical Co., Ltd.
Non-randomizedSingle-groupOpen-labelTreatment

Summary

The objective of this study is to investigate the safety, pharmacokinetics, pharmacology and efficacy of ONO-4538 administered to Korean patients with advanced or recurrent solid tumors who are refractory or intolerant to standard therapy or for whom no appropriate treatment is available.

Timeline

Start
2014-10
Primary completion
2015-06
Completion
2020-04

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Nivolumab Monoclonal antibody 1 mg/kg —
Subject Nivolumab Monoclonal antibody 3 mg/kg —
Subject Nivolumab Monoclonal antibody 10 mg/kg —

Indications

cancer